LXEO
Lexeo Therapeutics, Inc.
$9.77
-$0.03(-0.31%)
49
Overall
50
Value
63
Tech
34
Quality
Market Cap
$680.97M
Volume
681.92K
52W Range
$1.45 - $10.38
Target Price
$19.40
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $654.0K | $-530.0K | -- | ||
| Total Revenue | $654.0K | $-530.0K | -- | ||
| GROSS PROFIT | |||||
| Gross Profit | $654.0K | $-530.0K | -- | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $61.2M | $68.5M | $105.8M | ||
| Research & Development | $49.2M | $53.1M | $74.1M | ||
| Research Expense | $49.2M | $53.1M | $74.1M | ||
| Selling, General & Administrative | $12.0M | $15.4M | $31.7M | ||
| General & Administrative Expenses | $12.0M | $15.4M | $31.7M | ||
| Salaries & Wages | -- | $3.0M | $12.5M | ||
| Amortization | -- | $306.0K | $325.0K | ||
| Other Operating Expenses | -- | $2.5M | $2.6M | ||
| OPERATING INCOME | |||||
| Operating income | $-60.5M | $-68.5M | $-105.8M | ||
| EBITDA | -- | $-64.4M | $-96.2M | ||
| NON-OPERATING ITEMS | |||||
| Interest Expense (Non-Operating) | $91.0K | $176.0K | $127.0K | ||
| Intinc | $1.3M | $2.9M | $7.6M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $2.9M | $7.6M | ||
| Gain on Sale of Securities | -- | -- | $-103.0K | ||
| Other Income/Expense | $2.0K | $13.0K | $89.0K | ||
| Other Special Charges | $-2.0K | $-13.0K | $14.0K | ||
| PRE-TAX INCOME | |||||
| EBIT | -- | $-66.2M | $-98.2M | ||
| Pre-Tax Income | $-59.3M | $-66.4M | $-98.3M | ||
| NET INCOME | |||||
| Net Income | $-59.3M | $-66.4M | $-98.3M | ||
| Net Income (Continuing Operations) | $-59.3M | $-66.4M | $-98.3M | ||
| Net Income (Discontinued Operations) | $-59.3M | $-66.4M | $-98.3M | ||
| Net Income (Common Stockholders) | $-59.3M | $-66.4M | $-98.3M | ||
| Normalized Income | -- | -- | $-97.3M | ||
| TOTALS | |||||
| Total Expenses | $61.2M | $68.5M | $105.8M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $1.6M | $5.4M | $31.8M | ||
| Average Shares Outstanding (Diluted) | $1.6M | $5.4M | $31.8M | ||
| Shares Outstanding | $54.0M | $26.7M | $33.2M | ||
| Basic EPS | $-36.36 | $-12.4 | $-3.09 | ||
| Basic EPS (Continuing Operations) | $-36.36 | $-12.4 | $-3.09 | ||
| Diluted EPS | $-36.36 | $-12.4 | $-3.09 | ||
| Diluted EPS (Continuing Operations) | $-36.36 | $-12.4 | $-3.09 | ||
| OTHER METRICS | |||||
| Other Gand A | $12.0M | $15.4M | $31.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LXEO | $9.77 | -0.3% | 681.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Lexeo Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW